Effect of all‐trans‐Retinoic acid on the hypercoagulable state of patients with breast cancer
Open Access
- 30 April 2002
- journal article
- clinical trial
- Published by Wiley in American Journal of Hematology
- Vol. 70 (1) , 9-15
Abstract
To evaluate whether all‐trans‐retinoic acid (ATRA) is able to modulate the hemostatic system in patients with solid tumors, we studied patients with locally advanced breast cancer who were enrolled in a Phase Ib study of ATRA ± Tamoxifen (Tam). In this study, two groups of 15 patients/each were treated for 21 days before operation with ATRA at three doses (15, 45, or 75 mg/m2/day on alternate days) given alone (group 1) or in combination with Tam (group 2). One additional group received Tam alone. Plasma samples were evaluated for hypercoagulation markers (FVIIa, F1+2, TAT, D‐dimer), fibrinolysis proteins (t‐PA, PAI‐1), and coagulation inhibitors (protein C, AT). At baseline, cancer patients had FVIIa, F1+2, TAT, and PAI‐1 significantly greater than control subjects. During treatment, in the patients given ATRA alone, hypercoagulation markers appeared unmodified. Instead, subjects given Tam alone had a significant elevation of FVIIa, F1+2, and TAT versus baseline. However, in the ATRA + Tam groups, hypercoagulation markers were decreased compared with Tam alone. These results suggest that in selected conditions, pre‐operative ATRA may modulate the hypercoagulable state of breast cancer patients. Am. J. Hematol. 70:9–15, 2002.Keywords
This publication has 37 references indexed in Scilit:
- The Thrombophilic State Induced by Therapeutic Agents in the Cancer PatientSeminars in Thrombosis and Hemostasis, 1999
- Prevention of Venous Thromboembolism in Cancer PatientsSeminars in Thrombosis and Hemostasis, 1999
- All‐trans‐RETINOIC ACID INCREASES ADHESION TO ENDOTHELIUM OF THE HUMAN PROMYELOCYTIC LEUKAEMIA CELL LINE NB4British Journal of Haematology, 1996
- Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell linesCancer Letters, 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994
- Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgeryBritish Journal of Haematology, 1993
- The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysisBlood Coagulation & Fibrinolysis, 1993
- Hemostatic alterations in cancer patientsCancer and Metastasis Reviews, 1992
- Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von willebrand factor and tissue‐type plasminogen activatorAmerican Journal of Hematology, 1992
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast CancerNew England Journal of Medicine, 1988